Analyzing Genmab A/S (NASDAQ:GMAB) & Whitehawk Therapeutics (NASDAQ:WHWK)

Whitehawk Therapeutics (NASDAQ:WHWK) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Whitehawk Therapeutics and Genmab A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14 million	32.82	-$20.60 million	($1.12)	-3.67
Genmab A/S	$3.72 billion	5.44	$963.00 million	$1.27	25.57

Genmab A/S has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Whitehawk Therapeutics and Genmab A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Genmab A/S	19.08%	14.89%	7.73%

Insider & Institutional Ownership

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Whitehawk Therapeutics and Genmab A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	6	0	2.62
Genmab A/S	0	3	9	1	2.85

Whitehawk Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 99.51%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 21.65%. Given Whitehawk Therapeutics’ higher probable upside, equities research analysts plainly believe Whitehawk Therapeutics is more favorable than Genmab A/S.

Volatility & Risk

Whitehawk Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Summary

Genmab A/S beats Whitehawk Therapeutics on 11 of the 15 factors compared between the two stocks.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.